Evotec AG (NASDAQ:EVO) Short Interest Update

Evotec AG (NASDAQ:EVO) was the target of a large growth in short interest in February. As of February 27th, there was short interest totaling 352,335 shares, a growth of 36.3% from the February 12th total of 258,431 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average daily volume of 112,820 shares, the days-to-cover ratio is currently 3.1 days. Based on an average daily volume of 112,820 shares, the days-to-cover ratio is currently 3.1 days. Approximately 0.1% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evotec in a research note on Monday, December 29th. Berenberg Bank assumed coverage on shares of Evotec in a research report on Tuesday, February 3rd. They set a “buy” rating for the company. Finally, Wall Street Zen upgraded shares of Evotec from a “sell” rating to a “hold” rating in a report on Saturday, January 10th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $7.00.

Institutional Trading of Evotec

Several institutional investors have recently made changes to their positions in EVO. XTX Topco Ltd lifted its position in shares of Evotec by 25.1% during the fourth quarter. XTX Topco Ltd now owns 18,469 shares of the company’s stock valued at $57,000 after purchasing an additional 3,709 shares in the last quarter. Wellington Management Group LLP grew its position in Evotec by 25.7% in the 4th quarter. Wellington Management Group LLP now owns 1,797,444 shares of the company’s stock worth $5,536,000 after purchasing an additional 367,545 shares in the last quarter. OLD Mission Capital LLC purchased a new stake in Evotec in the 4th quarter valued at about $158,000. Millennium Management LLC bought a new position in shares of Evotec during the 4th quarter worth approximately $317,000. Finally, Marshall Wace LLP bought a new position in shares of Evotec during the 4th quarter worth approximately $40,000. Institutional investors own 5.81% of the company’s stock.

Evotec Price Performance

Evotec stock traded up $0.07 during trading on Monday, hitting $2.38. 183,081 shares of the company were exchanged, compared to its average volume of 144,283. The business’s 50 day moving average is $3.43 and its 200 day moving average is $3.44. Evotec has a 52 week low of $2.31 and a 52 week high of $4.80. The company has a current ratio of 2.12, a quick ratio of 2.03 and a debt-to-equity ratio of 0.48.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.